Trial · NCT00385255
Results by group456
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 456
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens | Boostrix+Fluarix 19-64 YOA Group | Anti-D | 677 | Participants | |
| Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens | Fluarix Boostrix 19-64 YOA Group | Anti-D | 614 | Participants | |
| Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens | Boostrix+Fluarix ≥ 65 YOA Group | Anti-D | 93 | Participants | |
| Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens | Fluarix Boostrix ≥ 65 YOA Group | Anti-D | 79 | Participants | |
| Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens | Boostrix+Fluarix 19-64 YOA Group | Anti-T | 700 | Participants | |
| Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens | Fluarix Boostrix 19-64 YOA Group | Anti-T | 653 | Participants | |
| Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens | Boostrix+Fluarix ≥ 65 YOA Group | Anti-T | 105 | Participants | |
| Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens | Fluarix Boostrix ≥ 65 YOA Group | Anti-T | 95 | Participants | |
| Number of Subjects With Anti-T Antibody Concentrations ≥ the Assay Cut-off Value | Boostrix+Fluarix 19-64 YOA Group | 687 | Participants | ||
| Number of Subjects With Anti-T Antibody Concentrations ≥ the Assay Cut-off Value | Fluarix Boostrix 19-64 YOA Group | 621 | Participants | ||
| Number of Subjects With Anti-T Antibody Concentrations ≥ the Assay Cut-off Value | Boostrix+Fluarix ≥ 65 YOA Group | 94 | Participants | ||
| Number of Subjects With Anti-T Antibody Concentrations ≥ the Assay Cut-off Value | Fluarix Boostrix ≥ 65 YOA Group | 84 | Participants | ||
| Antibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens | Boostrix+Fluarix 19-64 YOA Group | Anti-PT | 57.5 | 95% Confidence Interval 53.1 to 62.3 | EL.U/mL |
| Antibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens | Fluarix Boostrix 19-64 YOA Group | Anti-PT | 76.9 | 95% Confidence Interval 71.1 to 83.2 | EL.U/mL |
| Antibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens | Boostrix+Fluarix ≥ 65 YOA Group | Anti-PT | 51.2 | 95% Confidence Interval 40.8 to 64.2 | EL.U/mL |
| Antibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens | Fluarix Boostrix ≥ 65 YOA Group | Anti-PT | 59.3 | 95% Confidence Interval 47.0 to 74.8 | EL.U/mL |
| Antibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens | Boostrix+Fluarix 19-64 YOA Group | Anti-FHA | 467.6 | 95% Confidence Interval 434.9 to 502.8 | EL.U/mL |
| Antibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens | Fluarix Boostrix 19-64 YOA Group | Anti-FHA | 663.3 | 95% Confidence Interval 613.3 to 717.4 | EL.U/mL |
| Antibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens | Boostrix+Fluarix ≥ 65 YOA Group | Anti-FHA | 502.5 | 95% Confidence Interval 409.5 to 616.7 | EL.U/mL |
| Antibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens | Fluarix Boostrix ≥ 65 YOA Group | Anti-FHA | 669.6 | 95% Confidence Interval 539.1 to 831.8 | EL.U/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00385255/results